TRIM9 Interacts with ZEB1 to Suppress Esophageal Cancer by Promoting ZEB1 Protein Degradation via the UPP Pathway

Figure 3

Influence of TRIM9 on chemoresistance of KYSE-410 cells. (a, b) IC50 level detection of chemoagents including fluorouracil and cisplatin treated on esophageal cancer cells. KYSE-410 and KYSE-30 cell line groups were treated with TRIM9-specific shRNAs and overexpression vectors. (c, d) Chemoresistance evaluation of KYSE-30/KYSE-410 cell line groups under the treatment of 5-FU, cisplatin, or paclitaxel. Cancer cells in each of the groups were separately transfected with TRIM9-specific shRNAs and overexpression vectors/control vectors. (e, f) WB/quantitative RT-PCR detection of cancer stem-like cell biomarker (CD133/CD44) levels. Tumor cells in each group were separately treated with TRIM9-specific shRNAs or TRIM9-specific overexpression vectors and negative control vectors.

(a)

(b)

(c)

(d)

(e)

(f)